February 2018 Volume 14, Issue 2
Volume 14, Issue 2 | February 2018
February 2018
In this Issue
Diagnostics
Agendia’s MammaPrint prepares for Europe
Company teams up with Institut Curie for kit validationBreast cancer biomarkers
Immune checkpoint blockade therapy could be promisingEast meets West for MoU
BGI, Hummingbird Diagnostics join hands for early diagnosis of Alzheimer’s and Parkinson's diseasesIllumina partners with KingMed
Companies aim to develop NGS technology for Chinese FDA approvalDiagnostic technology goes 3D
New research study demonstrates applicability of VisionGate’s Cell-CT platformDiscovery
Microbial mysteries
TSRI unlocks secrets of deadly virus and finds clues to cancer treatment in bacteriaCrohn’s and Parkinson’s in cahoots?
Gene mutations found in Crohn’s patients suggest possible link with Parkinson’s diseaseThe new ‘IT’ thing in drug discovery
Global pharma drug discovery IT solutions to reach $5.3B by 2020, says Frost & SullivanMuscling up on stem cells
Researchers track muscle stem cell dynamics in response to injury and agingA new way to treat diabetes
Follicum identifies receptors in insulin-producing cells for potential new class of diabetes drugsResearch & Development
A meeting of metabolomics
Biocrates Life Sciences acquires Metanomics HealthPotentially powerful cancer biomarker identified
Protein expression may predict risk of colorectal cancer recurrenceMaking the ‘best’ better
Media system extends lifespan of functional neurons to advance neurodegenerative researchMVA-VLP platform is ‘MVP’ in new collaboration
GeoVax, Vaxeal will apply GeoVax’s MVA-VLP platform to generate cancer vaccinesAgilent collaborates with USC
Team-up aims to facilitate transformational biomedical science and engineering researchFeature
SOT/ToxExpo Show Preview: Texas welcomes back SOT
The Society of Toxicology revisits sunny San Antonio five years laterSpecial Focus on Cancer Research News: An eye on immunotherapeutics
A roundup of recent research efforts to advance immuno-oncology effortsSpecial Reports
Special Report on Cardiovascular Disease: Breaking the non-code
Heart scientists look to small RNAs for clues to pathology and treatmentEditor's Focus
Editor’s focus: Whose business is it, anyway?
In the healthcare realm, outside forces with money, resources and will are moving in to take charge of costs and efficiencies. The question is, will they really be able to make a difference, and how long before we see similar activity in pharma and biotech?Business & Government Policy
Patent Docs: Supreme Court expansion of patent-limiting doctrine puts branded drugs at risk
The significance of the legal decision to pharmaceutical products and the patents that protect their exclusivity arises from the aspect of the decision relating to exhaustion cause by foreign salesCelgene to acquire Juno for $9 billion
Acquisition will add novel scientific platform and manufacturing expertise to Celgene’s research and operational capabilitiesGeneration Bio launches into genetic medicine
Startup aims to develop truly drug-like genetic medicines based on its GeneWave technologyOn the cutting edge
A roundup of instrumentation, software and other tools and technology newsVical restructures to focus on HSV-2 and antifungal programs
Company expects to report that it ended 2017 with cash and investments of approximately $60M to $65MContract Services
What’s in a name?
Two contract services providers change their monikers as part of strategic shiftsRoom to grow
Rho builds new headquarters to meet needs of growing contract research operationsA new COO and a bigger footprint
Cromos looks to establish a more global presencePreclinical
Pioneering solid-tumor cancer program
NANOBIOTIX partners with Providence Cancer Institute for immunotherapeutic preclinical researchNew subsidiary, new AAV gene therapies
The most promising novel treatment, Tamid-001, may stop hereditary ocular diseaseTest-driving a potential autism drug
Research shows drug candidate NitroSynapsin helps correct signaling imbalances in animal modelsSaniona selects preclinical candidate
New potential therapy resides in GABAA α2/α3 program for neuropathic pain and chronic itchingClinical Trials
A second candidate against MDR infections
Achaogen boasts positive top-line results from first clinical trial of oral antibacterial C-ScapeTwo big hits for Agios
Presentations showcase company’s development in cancer treatmentBeating back the bipolar blues
Primary endpoint met in study of patients treated with cariprazine for acute bipolar I depressionHunter syndrome slips Shire’s net
Shire announces disappointing top-line results for SHP609 trial in children with Hunter syndrome and cognitive impairmentCommentary
Guest Commentary: Turning text into insights
There is too much published research for a person to keep up with; fortunately, with the right technology, such as text mining tools, researchers can overcome this challengeCatching the wave in 2018
Peter Kissinger takes some time to answer a few questions from readers of his column
Subscribe to our eNewsletters
Stay connected with all of the latest from Drug Discovery News.
SubscribeSponsored
Improving ALS research with pluripotent stem cell-derived models
Discover new advancements in modeling amyotrophic lateral sclerosis.
Automating 3D cell selection
Discover precise automated tools for organoid and spheroid handling.
A closer look at the tumor microenvironment
New technologies are allowing researchers to delve deeper into the complex tumor landscape.
